Optima Health plc (OPT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Optima Health plc stock £1.62, price £2.47, that is 34.5% below the price, quality 39 out of 100. Rating: overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
25‑month range £1.40 – £2.55 · fair‑value band £0.9010 – £1.75 · the £2.47 price screens above the £1.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Optima Health in your weekly email
Every Wednesday you see whether Optima Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Optima Health plc provides occupational health and wellbeing services for the public and private sectors in the United Kingdom.
Show moreShow less
The company offers strategy and advisory services; risk and compliance services comprising health surveillance, pre-placement, fitness for work, immunizations, and pensions; performance and attendance services, including attendance and productivity management; engagement and wellbeing services through digital platforms, health assessments, and onsite activities; mental health services; and musculoskeletal health services.
It serves the energy and utilities, construction, manufacturing, rail, transport, and financial sectors; and NHS, central, and local governments. The company was founded in 1947 and is headquartered in Sheffield, the United Kingdom.
Stock analysis
Optima Health plc (OPT) currently trades at £2.47, while our model-based Fair Value estimate is £1.62, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of £2.79 per share, and 5 of the 20 models we run sit above the £2.47 price.
Bear case: the Earnings-Based group reads lowest at £0.2700, and 15 of the 20 models stay below the price. Data coverage for this calculation is high.
Scenario range: £0.9010 (bear) to £1.75 (bull), the price of £2.47 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Optima Health plc reported revenue of £121M in FY2026 versus £22.4M in FY2022, a compound +52.4%/yr. Reported net income was £1.4M in FY2026.
Key figures
Market cap £268M Small · P/E ratio 123.3 · P/S ratio 2.22 · EPS (TTM) £0.0200 · Dividend yield 7.8% · Net margin 1.2% · Return on equity 0.8% · Return on assets (EBIT) 0.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −34%, OPT screens richer than that median.
Fair Value models
Bear£0.9010Fair Value £1.62Bull£1.75
Price £2.47 · Downside -34.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (£0.0122 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income£0.9100£0.9500£1.0373
FCF DCF£1.24£2.28£5.1671
Growth DCF£1.15£2.50£4.9370
All 21 models by family
DCF Models
FCF DCF£1.24£2.28£5.1671
Owner Earnings£1.30£3.45£7.5767
5Y Revenue Exit£0.2100£0.6100£1.3563
5Y EBITDA Exit£0.9600£2.21£4.4967
5Y P/E Exit£0.1200£0.4900£0.920062
10Y Revenue Exit£0.5300£1.20£1.7762
10Y EBITDA Exit£1.04£2.55£5.2960
10Y P/E Exit£0.4700£1.02£1.8358
Earnings-Based
Graham-Dodd£0.0900£0.6100£0.860060
Lynch FV£0.1900£0.2700£0.350058
PEG = 1.0£0.1900£0.2700£0.350055
Dividend Discount
Gordon GGM£1.57£2.94£4.2164
DDM Multi-Stage£1.57£2.63£3.1364
Multiples
P/E Multiple£0.2100£0.2800£0.350063
P/S Multiple£0.1600£0.2200£0.270058
EV/EBITn/an/a£0.100061
EV/EBITDA£0.7900£1.28£1.7766
Growth DCF
Growth DCF£1.15£2.50£4.9370
Rev-Margin DCF£0.2100£0.7200£1.4863
Economic Profit
Residual Income£0.9100£0.9500£1.0373
Growth Earnings
Growth-Adj P/E£0.2600£0.3700£0.480065
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
’22
’23
’24
’25
’26
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+71.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+63.6%
Dividend (yield on the price)7.8%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2% → 3%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+19.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +12.6% a year for the price and +16.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (22 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−34.5% · Below median
Profitability
Return on equity (12 months)0.8% · Below median
Return on assets0.4% · Below median
Net margin (12 months)1.2% · Below median
Operating margin (12 months)2.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)12.7% · Above median
Dividend yield (12 months)7.8% · Top 25%
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)123.3× · Priciest 25%
P/B1.58× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.22× · Cheaper than median
Price / free cash flow (fiscal year)20.3× · Cheaper than median
EV/EBITDA32.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)64· sector 46
PAST (return on equity)3· sector 10
HEALTH (low debt)75· sector 98
DIVIDEND (yield)100· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Optima Health plc Fair Value". https://www.fairvalue-calculator.com/stock/OPT
Frequently asked questions
Is Optima Health plc (OPT) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of £1.62 versus a price of £2.47, about 34% lower (overvalued).
What is the fair value of OPT?
Our model-based fair value for Optima Health plc is £1.62 (as of Nov 8, 2026), built from audited fundamentals. The current price: £2.47.
What is the quality score of OPT?
Optima Health plc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Optima Health plc (OPT)?
Our model-based price target is the fair value of £1.62 (as of Nov 8, 2026) from 21 valuation models. Cautious scenario £0.9010, optimistic scenario £1.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Optima Health plc stock forecast for 2026?
Our models put fair value at £1.62, about 34% lower versus a price of £2.47 (overvalued). Cautious scenario £0.9010, optimistic scenario £1.75. The calculation is refreshed regularly with new filings.
What is the revenue of Optima Health plc (OPT)?
Optima Health plc reported trailing-twelve-month revenue of about £121M (latest available figure, as of Nov 8, 2026).
Does Optima Health plc pay a dividend?
Optima Health plc currently shows a dividend yield of 7.83% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Optima Health plc (OPT)?
Optima Health plc has a dividend yield of 7.8%.
What growth is priced into Optima Health plc (OPT)?
For today's price to be fair in a discounted-cash-flow model, Optima Health plc would have to grow free cash flow by +15.2 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +52.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of OPT use?
Our models discount Optima Health plc at 10.3 %: a base by market capitalisation (small), damped by beta 0.28, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Optima Health plc that is +15.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Optima Health plc (OPT) delivered so far?
Over the past 4 years revenue at Optima Health plc grew +52.4 % a year. The price currently implies free-cash-flow growth of +15.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Optima Health plc (OPT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Optima Health plc (+15.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Optima Health plc (OPT)?
The free-cash-flow yield on the price is 5.62 %: that much free cash flow Optima Health plc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Optima Health plc (OPT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Optima Health plc it is £1.62 per share (as of Nov 8, 2026), against a price of £2.47. It is the blended result of 21 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Optima Health plc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, OPT trades above its calculated fair value: price £2.47, fair value £1.62, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPT?
No. The price is what the market pays today (£2.47); the fair value is what the company's own numbers justify (£1.62). For Optima Health plc the two are £0.8500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Optima Health plc worth?
The market values Optima Health plc at about £268M (market capitalisation, as of Nov 8, 2026). Per share that is £2.47; our models calculate a fair value of £1.62 per share.
What do the bullish and bearish scenarios say about OPT?
Our models span a range for Optima Health plc: cautious scenario £0.9010, base £1.62, optimistic £1.75 per share (as of Nov 8, 2026, price £2.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OPT?
Optima Health plc trades at a price-to-earnings ratio of 123.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £1.62 is built from several models across several years. Other multiples: P/B 1.6, P/S 2.2, EV/EBITDA 32.4.
How solid is the balance sheet of Optima Health plc (OPT)?
Balance-sheet figures for Optima Health plc (as of Nov 8, 2026): return on equity 0.8%, debt of 0.51 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is OPT from its 52-week high?
Optima Health plc trades at £2.47, about 3% below its 52-week high of £2.55 and 38% above the low of £1.78 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £1.62 is for.
Which stocks are comparable to Optima Health plc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Optima Health plc stock attractive at the current price?
The data as of Nov 8, 2026: price £2.47, calculated fair value £1.62 (−34%), Quality Score 39/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPT calculated?
We run Optima Health plc through 21 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £1.62 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Optima Health plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Optima Health plc (OPT)?
The closing price on Nov 6, 2026 was £2.47. Our model-based fair value is £1.62, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Optima Health plc right now?
The price sits above even our optimistic bull case (£1.75). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (£0.9010 to £1.75) leaves room in how you read the outcome.
Key figures of Optima Health plc
How large is the market capitalisation of Optima Health plc (OPT)?
The market capitalisation of Optima Health plc is £268M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Optima Health plc (OPT)?
The price-to-sales ratio of Optima Health plc is 2.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Optima Health plc (OPT)?
Earnings per share at Optima Health plc are £0.0200 (price ÷ EPS = P/E 123.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Optima Health plc (OPT)?
The dividend yield of Optima Health plc is 7.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Optima Health plc (OPT)?
The net margin of Optima Health plc is 1.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Optima Health plc (OPT)?
The return on equity (ROE) of Optima Health plc is 0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Optima Health plc (OPT)?
On an EBIT basis the return on assets of Optima Health plc is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Optima Health plc (OPT)?
The operating margin of Optima Health plc is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Optima Health plc (OPT)?
Revenue at Optima Health plc is growing +12.7% versus a year earlier (3y avg +1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Optima Health plc (OPT)?
Earnings per share at Optima Health plc are growing −90.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Optima Health plc (OPT) carry?
The net debt of Optima Health plc is £73.4M (fiscal year 2026, ≈ 5.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Optima Health plc in the live analysis
One click puts Optima Health plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026